GERNGeron Corp

CSNasdaq (XNAS)·USD

Identity

Security key: 15935
Ticker: GERN
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 1996-07-31
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: GERN

Detail

Enriched 2026-08-14 20:47

Market cap: $1,007,187,929.18
Shares outstanding (class): 642,473,409
Shares outstanding (weighted): 641,520,974
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 258
Location: FOSTER CITY, CA
Homepage: https://www.geron.com
Description: Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Market cap and share counts drift.

Funds holding this security

63 funds · 63 positions · $109.85M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$29.88M	0.00%	20,054,534 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$24.75M	0.33%	16,613,693 NS	FIGI
iShares Russell 2000 ETF iShares Trust	IWM	$19.86M	0.03%	13,330,333 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$8.87M	0.01%	5,952,241 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$6.72M	0.08%	4,513,103 NS	FIGI
iShares Russell 2000 Growth ETF iShares Trust	IWO	$6.69M	0.05%	4,487,386 NS	FIGI
ClearBridge Variable Small Cap Growth Portfolio Legg Mason Partners Variable Equity Trust	—	$2.00M	0.51%	1,343,700 NS	FIGI
Master Small Cap Index Series Quantitative Master Series LLC	—	$1.28M	0.03%	857,465 NS	FIGI
iShares Core S&P Total U.S. Stock Market ETF iShares Trust	ITOT	$1.05M	0.00%	703,412 NS	FIGI
Variable Portfolio - Partners Small Cap Value F… Columbia Funds Variable Series Trust II	—	$968.3K	0.24%	649,870 NS	FIGI
EQ/2000 Managed Volatility Portfolio EQ Advisors Trust	—	$854.9K	0.03%	573,731 NS	FIGI
Fidelity Small Cap Growth Index Fund Fidelity Salem Street Trust	—	$618.8K	0.05%	415,297 NS	FIGI
TIFF MULTI-ASSET FUND TIFF Investment Program	—	$558.1K	0.04%	374,534 NS	FIGI
LVIP SSGA Small-Cap Index Fund LINCOLN VARIABLE INSURANCE PRODUCTS TRUST	—	$545.8K	0.03%	366,294 NS	FIGI
VANGUARD BALANCED INDEX FUND VANGUARD VALLEY FORGE FUNDS	—	$535.7K	0.00%	359,553 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERGERN
FIGI_COMPOSITEBBG000GX1891
FIGI_SHARE_CLASSBBG001S6TSX4
CIK0000886744
ISINUS3741631036
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.85
Model: deepseek
Rationale: Geron is a clinical-stage biopharmaceutical company focused on oncology, fitting the biotechnology industry.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.